Mitigating Toxicities Arising From Combination Therapies in RCC
March 29th 2023Combination therapy with checkpoint blockade, also termed immuno oncology agents, and multikinase tyrosine kinase inhibitors are rapidly becoming the first-line therapy of choice in patients with metastatic clear cell renal cell carcinoma.